CA2577288A1 - Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile - Google Patents
Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile Download PDFInfo
- Publication number
- CA2577288A1 CA2577288A1 CA002577288A CA2577288A CA2577288A1 CA 2577288 A1 CA2577288 A1 CA 2577288A1 CA 002577288 A CA002577288 A CA 002577288A CA 2577288 A CA2577288 A CA 2577288A CA 2577288 A1 CA2577288 A1 CA 2577288A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- composition according
- formula
- compound
- wetting agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title claims abstract 4
- YIBOMRUWOWDFLG-UHFFFAOYSA-N 4-[[4-[4-(2-cyanoethenyl)-2,6-dimethylanilino]pyrimidin-2-yl]amino]benzonitrile Chemical compound CC1=CC(C=CC#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 15
- 239000004480 active ingredient Substances 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims abstract 3
- 238000002360 preparation method Methods 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000011230 binding agent Substances 0.000 claims 4
- 239000000080 wetting agent Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 238000002156 mixing Methods 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 2
- VERWQPYQDXWOGT-LVJNJWHOSA-N 4-amino-5-fluoro-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;[[(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VERWQPYQDXWOGT-LVJNJWHOSA-N 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000007888 film coating Substances 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- 239000008247 solid mixture Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MYPI20043578A MY169670A (en) | 2003-09-03 | 2004-09-02 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| MYPI20043578 | 2004-09-02 | ||
| EPPCT/EP2004/052028 | 2004-09-03 | ||
| PCT/EP2004/052028 WO2005021001A1 (fr) | 2003-09-03 | 2004-09-03 | Combinaisons d'une pyrimidine renfermant nnrti avec des inhibiteurs de rt |
| EP05101467 | 2005-02-25 | ||
| EP05101467.8 | 2005-02-25 | ||
| PCT/EP2005/054342 WO2006024668A1 (fr) | 2004-09-02 | 2005-09-02 | Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2577288A1 true CA2577288A1 (fr) | 2006-03-09 |
| CA2577288C CA2577288C (fr) | 2010-11-30 |
Family
ID=34940340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2577288A Active CA2577288C (fr) | 2004-09-02 | 2005-09-02 | Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
Country Status (5)
| Country | Link |
|---|---|
| KR (1) | KR101284361B1 (fr) |
| AU (1) | AU2005279158C1 (fr) |
| CA (1) | CA2577288C (fr) |
| PL (1) | PL1632232T6 (fr) |
| WO (1) | WO2006024668A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| EA014914B1 (ru) * | 2006-01-20 | 2011-02-28 | Тиботек Фармасьютикалз Лтд. | Долговременное лечение вич-инфекции |
| CL2008000746A1 (es) | 2007-03-14 | 2008-09-22 | Tibotec Pharm Ltd | Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida. |
| UA97971C2 (ru) * | 2007-06-08 | 2012-04-10 | Берингер Ингельхайм Интернациональ Гмбх | Препарат невирапина пролонгированного высвобождения |
| SI2175857T1 (sl) * | 2007-07-12 | 2014-01-31 | Janssen R&D Ireland | Kristalna oblika (E) 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino) 2-pirimidinil)amino)benzonitrila |
| AU2011209788C1 (en) | 2010-01-27 | 2014-08-28 | Viiv Healthcare Company | Antiviral therapy |
| CN106511357A (zh) | 2010-11-19 | 2017-03-22 | 吉利德科学公司 | 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物 |
| WO2012125993A1 (fr) | 2011-03-17 | 2012-09-20 | Teva Pharmaceutical Industries Ltd. | Formes à l'état solide de base rilpivirine et sels de rilpivirine |
| ES2680146T3 (es) * | 2011-09-16 | 2018-09-04 | Hetero Research Foundation | Hidrocloruro de rilpivirina |
| WO2013087794A1 (fr) * | 2011-12-14 | 2013-06-20 | Sandoz Ag | Polymorphe de chlorhydrate de rilpivirine et son utilisation à titre d'antiviral |
| EP2604593A1 (fr) * | 2011-12-14 | 2013-06-19 | Sandoz AG | Polymorphe du chlorhydrate de rilpivirine et son utilisation comme antiviral |
| JP7197474B2 (ja) | 2016-10-24 | 2022-12-27 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | 分散性組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| MY169670A (en) * | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| US7399856B2 (en) * | 2002-08-09 | 2008-07-15 | Janssen Pharmaceutica N.V. | Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-2pyrimidinyl]amino]benzonitrile |
-
2005
- 2005-09-02 PL PL05108086T patent/PL1632232T6/pl unknown
- 2005-09-02 WO PCT/EP2005/054342 patent/WO2006024668A1/fr active Application Filing
- 2005-09-02 AU AU2005279158A patent/AU2005279158C1/en active Active
- 2005-09-02 KR KR1020077006837A patent/KR101284361B1/ko active IP Right Review Request
- 2005-09-02 CA CA2577288A patent/CA2577288C/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005279158A1 (en) | 2006-03-09 |
| PL1632232T3 (pl) | 2011-10-31 |
| KR101284361B1 (ko) | 2013-07-15 |
| AU2005279158B2 (en) | 2010-06-17 |
| PL1632232T6 (pl) | 2022-06-27 |
| WO2006024668A1 (fr) | 2006-03-09 |
| KR20070074555A (ko) | 2007-07-12 |
| CA2577288C (fr) | 2010-11-30 |
| AU2005279158C1 (en) | 2010-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2577288A1 (fr) | Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile | |
| JP6875407B2 (ja) | Ｊａｋキナーゼ阻害剤またはその薬剤的に許容される塩を含有する医薬組成物 | |
| CA2606207C (fr) | Preparation pharmaceutique | |
| JP4977462B2 (ja) | ３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンズイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−プロピオン酸エチルエステルまたはその塩を含む錠剤 | |
| KR101041203B1 (ko) | 안정한 이매티닙 조성물 | |
| US9370577B2 (en) | Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa | |
| JP2010511663A5 (fr) | ||
| US20050191350A1 (en) | Stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof | |
| JP2008533191A5 (fr) | ||
| JP2008511592A5 (fr) | ||
| JP2002520316A5 (fr) | ||
| JP2008544975A5 (fr) | ||
| US20220184085A1 (en) | Solid pharmaceutical composition comprising tlr7 agonist | |
| US7612066B2 (en) | Composition containing benzamidine derivative and method for stabilizing benzamidine derivative | |
| US20130085145A1 (en) | Imatinib mesilate pharmaceutical tablet | |
| US9750700B2 (en) | Imatinib mesylate oral pharmaceutical composition and process for preparation thereof | |
| KR20180008511A (ko) | 제약 조성물 | |
| JP6937308B2 (ja) | キノリン誘導体またはその塩を含有する医薬組成物の製造方法 | |
| EP2529741A1 (fr) | Composition et comprimé comprenant raltégravir | |
| KR101276571B1 (ko) | 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 푸마레이트 | |
| US20200079740A1 (en) | Crystalline Form of Eluxadoline | |
| EP2065035A1 (fr) | Formules pharmaceutiques contenant de l'irbesartan | |
| HRP20120499T1 (hr) | Fumarat cijanoetenil dimetilfenil amino pirimidinil amino benzonitrila | |
| WO2007142546A2 (fr) | Comprimé enrobé à libération prolongée ayant un profil de libération précisement régulé | |
| EP2803353B1 (fr) | Compositions d'imatinib |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |